David Heathcote is Regional Manager (Europe) for a medical device manufacturer, Deputy Chair Political for Huddersfield & The Valleys Conservative Federation and Chair of the Calderdale, Kirklees & Wakefield Conservative Policy Forum.
Why Parliament must challenge the UK’s approach to prostate cancer screening
The UK National Screening Committee (UKNSC) recently advised the government against introducing a structured screening programme for prostate cancer, prompting clinicians, charities and over 120 MPs to warn that thousands of men are being left at risk. Under the leadership of Oliver Kemp MBE, Prostate Cancer Research has called for Parliament to scrutinise both the evidence behind the decision and the governance of the process, attracting wider public and parliamentary support.
Prostate cancer is the most commonly diagnosed cancer in the UK, affecting 1 in 8 men overall and 1 in 4 Black men. Each year around 64,000 men are diagnosed and more than 12,000 die, making it one of the nation’s biggest cancer killers. Despite this scale, current policy does not require routine testing for high‑risk groups including Black men and men with a family history, while targeted screening is recommended only for men aged 45–61 with a pathogenic BRCA2 variant and a relevant family history under current UKNSC guidance.
GPs are discouraged from promoting the available PSA test, and many men still have to ask for it themselves. Too many lives are lost because prostate cancer is diagnosed late, as recent public cases, including journalist and broadcaster Dermot Murnaghan, have highlighted.
The UKNSC has not only advocated maintaining the status quo, it has stepped back from earlier indications that targeted screening might be extended beyond men with a known BRCA2 variant and a relevant family history, leaving many high‑risk men without access to earlier detection.
The committee argues that routine screening should not be introduced because the PSA test can generate false positives, causing unnecessary anxiety and avoidable biopsies, while being unable reliably to distinguish aggressive cancers from harmless ones.
However, this argument overlooks a crucial fact: pre-biopsy MRI is now the recommended standard in the NHS diagnostic pathway.
This represents a major shift from the traditional medical approach, where an elevated PSA blood test automatically triggered an immediate, blind needle biopsy. MRI now acts as a triage tool, helping clinicians decide whether a biopsy is needed and where it is, guiding them to the suspicious area rather than relying on a blind biopsy.
European countries such as Sweden, Ireland, Poland, Lithuania, Italy and Spain are modernising PSA‑based screening by combining PSA testing with structured MRI triage. These programmes use nationally consistent PSA thresholds, defined screening intervals and clear MRI criteria to reduce false positives while still detecting clinically significant cancers earlier.
This is the key distinction Parliament should seek to understand. The UK’s current approach is unstructured and opportunistic: men are not routinely invited for testing, and there are questions about whether PSA thresholds, referral practices and access to MRI are applied consistently across local pathways and clinical interpretation. By contrast, European neighbours use structured PSA‑plus‑MRI screening. These programmes aim to test men in a consistent, structured way, with defined intervals and criteria. This standardisation reduces unnecessary MRIs and biopsies, cuts overdiagnosis dramatically and improves early detection.
There is significant doubt about the suitability of the data and modelling used by the UKNSC to support its conclusions. An independent review commissioned by Prostate Cancer Research raised structural concerns with the model, including its reliance on older evidence and assumptions that may not fully reflect modern MRI-led diagnostic pathways.
PCR’s own analysis of contemporary studies suggests a more favourable balance of benefit and harm from PSA-MRI triage than the UKNSC model implies. In a cohort of 1,000 men, the UKNSC model estimates around 100 positive PSA tests and 34 biopsies following a positive MRI scan, while PCR’s modelling estimates 59 positive PSA tests, leading to MRI and 12 subsequent biopsies.
PCR’s analysis also suggests lower overdiagnosis and overtreatment, while showing a similar or slightly greater number of lives saved. Overdiagnosis falls from up to 20 men in the UKNSC model to just 3 in PCR’s analysis, and overtreatment from around 12 men to 2. PCR’s modelling estimates around 2.2 lives saved per 1,000 men, compared with up to 2 lives saved under the UKNSC model.
Taken together, these findings raise serious questions about whether the potential harms of a national prostate cancer screening rollout have been overstated in the UKNSC’s modelling.
There are also serious concerns about the governance surrounding the screening committee’s decision. The minutes of the UKNSC meeting indicate that the committee did not substantively engage with the evidence submitted. More than 52 detailed submissions from world‑leading experts were dismissed as “misconceptions”. This raises questions about whether the committee met the Nolan Principles of transparency and accountability expected of a public body.
In June, ministers acknowledged the need to explore targeted screening for higher‑risk men and have asked the UKNSC to review options again. However, no commitment has been made and the committee’s restrictive advice remains unchanged.
In July, news regarding the UKNSC’s delay in evaluating the Stockholm3 test made front‑page headlines and was branded a “betrayal of trust”. This divergence between ministerial direction and advisory guidance reinforces the need for urgent parliamentary scrutiny.
The government is awaiting the outcomes of the TRANSFORM trial, which aims to find the best way to screen men for prostate cancer. Stage 1 will run for two years and the larger Stage 2 is set to begin in 2028. While the Government’s £18m investment in TRANSFORM is welcome, it cannot be used as a reason to delay action. TRANSFORM will generate future evidence, but the UKNSC’s decision concerns the evidence we already have.
Prostate Cancer Research’s petition, calling on the government to “Introduce a screening programme for prostate cancer, starting with high‑risk men”, recently exceeded 100,000 signatures, meaning the House of Commons Petitions Committee will consider it for debate. Members of Parliament should use any forthcoming debate to examine the evidence and ask why high‑risk men are still being denied a proactive route to earlier diagnosis, and to consider whether the screening committee’s process has met the standards of transparency and accountability expected by Parliament.
Opposition to the screening committee’s position is not confined to campaigners. Clinicians working on the front line warn that the current approach leaves too many men dependent on chance awareness, personal persistence or a well‑informed GP, rather than a health system that proactively identifies those most at risk.
Ministers have already acknowledged the case for exploring targeted screening for high‑risk men. Parliament should now ensure that this review is conducted openly, rigorously and without prejudice. For the thousands of men diagnosed with prostate cancer every year, this debate is not merely about process. It is about whether lives that could be saved through earlier diagnosis are being lost to institutional caution. High‑risk men should not have to wait for action.
David Heathcote is Regional Manager (Europe) for a medical device manufacturer, Deputy Chair Political for Huddersfield & The Valleys Conservative Federation and Chair of the Calderdale, Kirklees & Wakefield Conservative Policy Forum.
Why Parliament must challenge the UK’s approach to prostate cancer screening
The UK National Screening Committee (UKNSC) recently advised the government against introducing a structured screening programme for prostate cancer, prompting clinicians, charities and over 120 MPs to warn that thousands of men are being left at risk. Under the leadership of Oliver Kemp MBE, Prostate Cancer Research has called for Parliament to scrutinise both the evidence behind the decision and the governance of the process, attracting wider public and parliamentary support.
Prostate cancer is the most commonly diagnosed cancer in the UK, affecting 1 in 8 men overall and 1 in 4 Black men. Each year around 64,000 men are diagnosed and more than 12,000 die, making it one of the nation’s biggest cancer killers. Despite this scale, current policy does not require routine testing for high‑risk groups including Black men and men with a family history, while targeted screening is recommended only for men aged 45–61 with a pathogenic BRCA2 variant and a relevant family history under current UKNSC guidance.
GPs are discouraged from promoting the available PSA test, and many men still have to ask for it themselves. Too many lives are lost because prostate cancer is diagnosed late, as recent public cases, including journalist and broadcaster Dermot Murnaghan, have highlighted.
The UKNSC has not only advocated maintaining the status quo, it has stepped back from earlier indications that targeted screening might be extended beyond men with a known BRCA2 variant and a relevant family history, leaving many high‑risk men without access to earlier detection.
The committee argues that routine screening should not be introduced because the PSA test can generate false positives, causing unnecessary anxiety and avoidable biopsies, while being unable reliably to distinguish aggressive cancers from harmless ones.
However, this argument overlooks a crucial fact: pre-biopsy MRI is now the recommended standard in the NHS diagnostic pathway.
This represents a major shift from the traditional medical approach, where an elevated PSA blood test automatically triggered an immediate, blind needle biopsy. MRI now acts as a triage tool, helping clinicians decide whether a biopsy is needed and where it is, guiding them to the suspicious area rather than relying on a blind biopsy.
European countries such as Sweden, Ireland, Poland, Lithuania, Italy and Spain are modernising PSA‑based screening by combining PSA testing with structured MRI triage. These programmes use nationally consistent PSA thresholds, defined screening intervals and clear MRI criteria to reduce false positives while still detecting clinically significant cancers earlier.
This is the key distinction Parliament should seek to understand. The UK’s current approach is unstructured and opportunistic: men are not routinely invited for testing, and there are questions about whether PSA thresholds, referral practices and access to MRI are applied consistently across local pathways and clinical interpretation. By contrast, European neighbours use structured PSA‑plus‑MRI screening. These programmes aim to test men in a consistent, structured way, with defined intervals and criteria. This standardisation reduces unnecessary MRIs and biopsies, cuts overdiagnosis dramatically and improves early detection.
There is significant doubt about the suitability of the data and modelling used by the UKNSC to support its conclusions. An independent review commissioned by Prostate Cancer Research raised structural concerns with the model, including its reliance on older evidence and assumptions that may not fully reflect modern MRI-led diagnostic pathways.
PCR’s own analysis of contemporary studies suggests a more favourable balance of benefit and harm from PSA-MRI triage than the UKNSC model implies. In a cohort of 1,000 men, the UKNSC model estimates around 100 positive PSA tests and 34 biopsies following a positive MRI scan, while PCR’s modelling estimates 59 positive PSA tests, leading to MRI and 12 subsequent biopsies.
PCR’s analysis also suggests lower overdiagnosis and overtreatment, while showing a similar or slightly greater number of lives saved. Overdiagnosis falls from up to 20 men in the UKNSC model to just 3 in PCR’s analysis, and overtreatment from around 12 men to 2. PCR’s modelling estimates around 2.2 lives saved per 1,000 men, compared with up to 2 lives saved under the UKNSC model.
Taken together, these findings raise serious questions about whether the potential harms of a national prostate cancer screening rollout have been overstated in the UKNSC’s modelling.
There are also serious concerns about the governance surrounding the screening committee’s decision. The minutes of the UKNSC meeting indicate that the committee did not substantively engage with the evidence submitted. More than 52 detailed submissions from world‑leading experts were dismissed as “misconceptions”. This raises questions about whether the committee met the Nolan Principles of transparency and accountability expected of a public body.
In June, ministers acknowledged the need to explore targeted screening for higher‑risk men and have asked the UKNSC to review options again. However, no commitment has been made and the committee’s restrictive advice remains unchanged.
In July, news regarding the UKNSC’s delay in evaluating the Stockholm3 test made front‑page headlines and was branded a “betrayal of trust”. This divergence between ministerial direction and advisory guidance reinforces the need for urgent parliamentary scrutiny.
The government is awaiting the outcomes of the TRANSFORM trial, which aims to find the best way to screen men for prostate cancer. Stage 1 will run for two years and the larger Stage 2 is set to begin in 2028. While the Government’s £18m investment in TRANSFORM is welcome, it cannot be used as a reason to delay action. TRANSFORM will generate future evidence, but the UKNSC’s decision concerns the evidence we already have.
Prostate Cancer Research’s petition, calling on the government to “Introduce a screening programme for prostate cancer, starting with high‑risk men”, recently exceeded 100,000 signatures, meaning the House of Commons Petitions Committee will consider it for debate. Members of Parliament should use any forthcoming debate to examine the evidence and ask why high‑risk men are still being denied a proactive route to earlier diagnosis, and to consider whether the screening committee’s process has met the standards of transparency and accountability expected by Parliament.
Opposition to the screening committee’s position is not confined to campaigners. Clinicians working on the front line warn that the current approach leaves too many men dependent on chance awareness, personal persistence or a well‑informed GP, rather than a health system that proactively identifies those most at risk.
Ministers have already acknowledged the case for exploring targeted screening for high‑risk men. Parliament should now ensure that this review is conducted openly, rigorously and without prejudice. For the thousands of men diagnosed with prostate cancer every year, this debate is not merely about process. It is about whether lives that could be saved through earlier diagnosis are being lost to institutional caution. High‑risk men should not have to wait for action.